The reactivation of cytomegalovirus (CMV) in 71 astronauts was investigated, using polymerase chain reaction. A significantly greater ( ) shedding frequency was found in urine P ! .0001 samples from astronauts before spaceflight (10.6%) than in urine from the healthy control subject group (1.2%). Two of 4 astronauts studied during spaceflight shed CMV in urine. A significant increase ( ) in CMV antibody titer, compared with baseline values, was also found 10 P ! .0001 days before spaceflight. CMV antibody titer was further increased ( ) 3 days after landing, P ! .001 compared with 10 days before the mission. Significant increases in stress hormones were also found after landing. These results demonstrate that CMV reactivation occurred in astronauts before spaceflight and indicate that CMV may further reactivate during spaceflight.
Microgravity is a unique and unfamiliar environment for human beings. Because of its novelty, no preset adaptive responses exist; therefore, adaptation to the space environment may be perceived by the body as a stress. The sudden gravitational changes in spaceflight (e.g., launch acceleration followed by microgravity) may therefore be expected to elicit a stress response. Indeed, previous studies have shown increased levels of urinary cortisol and interleukin-6 on the first day of spaceflight [1] . The psychological and physical stressors associated with spaceflight may lead to the down-regulation of some aspects of the immune response [2] .
We previously investigated latent Epstein-Barr virus (EBV) reactivation in astronauts as a model for viral reactivation and found increased frequency of EBV shedding by astronauts before spaceflight [3] . Eight-fold or greater increases in anti-EBV antibodies were observed after spaceflight [4] . Previous ground-based studies conducted in the Antarctic demonstrated that EBV shedding increased, while cellular immunity diminished, during long periods of isolation [5, 6] . These studies suggested that decreased cellular immune function results in reactivation and shedding of potentially infectious viruses.
Another latent herpesvirus, human cytomegalovirus (CMV), may pose a similar kind of risk to the health of astronauts during spaceflight. CMV infection is usually acquired asymptomatically during childhood. However, in individuals whose immune system is either immature or compromised, CMV can cause a number of serious diseases, such as encephalitis, gastroenteritis, pneumonia, and chorioretinitis [7] . Moreover, CMV infection may contribute to preexisting immunosuppression by directly infecting leukocytes and hematopoietic cells [8] [9] [10] . We examined the effect of spaceflight on CMV reactivation to begin the process of assessing the health consequences of latent viruses during spaceflights of long duration.
Materials and Methods
Subjects. Urine samples were obtained from 71 crew members 10 ( ) and 3 ( ) days before launch and 2-3 h after land-L Ϫ 10 L Ϫ 3 ing ( ). The mean ages of the 58 male and 13 female astronauts R ϩ 0 were and years, respectively. Spaceflight con-43.1 ‫ע‬ 0.6 39.9 ‫ע‬ 0.8 straints allowed us to obtain in-flight urine samples collected on spaceflight days 2-4 from only 4 crew members. Urine samples were stored frozen until processed. Plasma for measurement of virus antibody titers and stress hormones was obtained from 71 astronauts at , , and 3 days after landing ( ) and was L Ϫ 10 R ϩ 0 R ϩ 3 stored at Ϫ70ЊC until processed.
Sixty-one healthy age-matched adults served as control subjects. One urine sample was obtained from each of these control subjects. Only 11 of the 61 control subjects, whose availability was limited, provided blood samples; additional urine samples were obtained from these 11 control subjects 7 and 22 days after the first urine sample. This collection schedule closely approximates the pre-and postspaceflight collection schedule of a 12-day spaceflight.
Viral DNA extraction and polymerase chain reaction (PCR). Three milliliters from each urine sample was concentrated to ∼200 mL by centrifugation (Microsep concentrator 100K; Pall Filtron, Northborough, MA). Viral DNA was extracted with a viral RNA kit (QIAamp; Qiagen, Chatsworth, CA), according to the manufacturer's instructions. Microcarrier gel (Molecular Research, Cincinnati) was added to facilitate DNA recovery. CMV DNA was amplified using primers that target the major immediate early gene: P1, 5 -TGT CCT CCC GCT CCT C; and P2, biotin 5 -ATG AAG GTC TTT GCC CAG TA. All reactions were carried out using the GenAmp System 9600 (Perkin-Elmer, Norwalk, CT). An initial denaturation step of 94ЊC for 9 min was followed by 40 cycles of 94ЊC for 30 s, 69ЊC for 15 s, 72ЊC for 30 s, 72ЊC for 7 min, and a 4ЊC hold. PCR products were analyzed by use of the Digene Sharp Signal System (Digene Diagnostics, Gaithersburg, MD). CMV copy numbers were measured (Viral Quant CMV quantitative PCR detection kit; BioSource International, Camarillo, CA) in CMVpositive samples.
Measurement of antiviral antibody titers. CMV IgG and measles IgG antibody titers were determined by indirect immunofluorescence assay, as described elsewhere [4] . Archived CMV antibody titer data were available from the annual medical examinations (average of 22 months before spaceflight) of the astronauts and were used as a baseline value for comparison with pre-and postspaceflight data.
Stress hormones. Hormones were measured as described elsewhere [4] . Adrenocorticotropic hormone, cortisol, and human growth hormone were measured by RIA. Urinary catecholamines (norepinephrine and epinephrine) were measured by high-performance liquid chromatography.
Statistical analysis. Zero-inflated negative binomial regression [11] was used to compare CMV copy numbers across spaceflight phases or between astronauts and control subjects. Descriptive statistics for CMV IgG antibody titers were displayed in terms of standard statistics (means, standard errors) calculated for log 2 antibody titers; however, because of the discrete nature of these antibody titration measurements, all statistical inference comparing specific spaceflight phases was done using the Wilcoxon signed rank test. In a similar manner, comparisons of hormone concentrations across time were made using Friedman's analysis of variance on ranks.
Results

CMV in urine.
Shedding of CMV in urine was detected by PCR at least once for 15 (21%) of 71 astronauts studied during the mission-monitoring period ( , LϪ3, and L Ϫ 10 ). By contrast, only 1 (1.6%) of 61 control subjects shed R ϩ 0 CMV during 1 sampling period. In general, shedding by astronauts was more prevalent before spaceflight than during or after spaceflight, with 10 subjects shedding at , 5 at LϪ3, L Ϫ 10 and 4 at . These included 1 subject shedding at all 3 time R ϩ 0 points and 3 shedding at 2 of the 3 time points. Of 71 astronauts, 55 (77%) were seropositive for CMV. CMV DNA was detected in 23 of 177 urine samples from the 55 seropositive astronauts, whereas only 1 of 33 samples from the control group was positive for CMV. No CMV was detected in urine of the 16 seronegative astronauts at any time.
Overall, shedding was observed in 15 (10.6%) of 142 prespaceflight urine samples from the astronauts, compared with only 1 (1.2%) of 82 urine samples from control subjects. In astronaut prespaceflight samples in which shedding occurred, copy numbers ranged from 56 to 896 copies/mL (mean, 202 copies/mL). The 1 control subject sample in which shedding had occurred had 45 copies/mL. Even allowing for the fact that multiple urine samples from some subjects were analyzed, the difference between the 2 groups was statistically significant ( ). At the same P ! .0001 time, we found no significant difference between pre-and postspaceflight distributions of CMV copy numbers for the 15 astronauts. The postspaceflight number of CMV copies ranged from 68 to 251 copies/mL (mean, 140 copies/mL).
In-flight measurements were available for only 4 astronauts, 2 of whom shed CMV at least once during that time. In urine samples from astronaut 15, CMV was detected on (259 L Ϫ 10 copies/mL) and spaceflight days 2 (388 copies/mL) and 3 (447 copies/mL); CMV was not detected on spaceflight day 4 or . Urine samples from astronaut 16 had no detectable levels R ϩ 0 of CMV before or after spaceflight, but this subject shed in 2 of the 3 in-flight samples that were obtained on spaceflight days 2 (421 copies/mL) and 3 (242 copies/mL).
CMV antibody titer. No significant changes in CMV antibody titer occurred before or after spaceflight within the group of 55 seropositive astronauts. However, when these subjects were divided into 40 nonshedders and 15 CMV shedders, an interesting difference was found. No significant changes from baseline were found in CMV IgG antibody titer at any time for nonshedders ( figure 1A ). In contrast, CMV antibody titers of the 15 shedders were significantly increased ( ) over P ! .001 their baseline values at all time points ( , , and L Ϫ 10 R ϩ 0 ). In addition, antibody was significantly increased at R ϩ 3 , compared with that at ( ). No significant R ϩ 3 L Ϫ 10 P ! .001 change was observed in the measles IgG antibody titer at or , compared with that at (data not shown), R ϩ 0 Rϩ 3 L Ϫ 10 and no changes in CMV IgG antibody titer from 11 CMVseropositive control subjects were found across 3 sampling times. These CMV antibody titers of the control subjects did not differ from the baseline levels of astronauts.
In 11 of the 15 astronauts who shed CMV in urine, anti-CMV antibody titer was increased у4-fold at versus L Ϫ 10 their baseline values. In 3 of the 15 subjects (data from 2 are shown in figures 1B and 1C) , a further increase (4-fold) in CMV antibody titer was observed at , compared with that at R ϩ 3 . In the remaining 12 subjects, no significant postspace-R ϩ 0 flight ( ) changes in CMV antibody titer were found. R ϩ 3 Stress hormones. Plasma cortisol, adrenocorticotropic hormone, and human growth hormone of 48 of the 55 CMVseropositive astronauts were measured at 3 time points (L Ϫ , , and ); the only statistically significant difference 10 R ϩ 0 Rϩ 3 at landing ( ) or , compared with that before spa-R ϩ 0 Rϩ 3 ceflight ( ), was a decrease in plasma cortisol ( ; L Ϫ 10 P ! .05 table 1). However, 24-h levels of urinary cortisol and catecholamines (epinephrine and norepinephrine) were significantly elevated at landing, compared with levels at LϪ10 ( ). Fur-P ! .05 ther analysis of samples from the 15 astronauts who shed CMV in urine showed no detectable difference in stress hormone levels, compared with those of the 40 nonshedders.
Discussion
To our knowledge, this is the first report of CMV reactivation and shedding in astronauts. We found that astronauts shed CMV in urine more frequently than did control subjects, and CMV antibody titer increased just before spaceflight in astronauts who shed CMV. In addition, a significant increase in CMV shedding frequency was observed before spaceflight in the astronaut group, compared with that in the control group. These results support and extend our previous observations [3, 4] that latent EBV reactivation increased significantly just before spaceflight, a finding that is consistent with a stress-induced decrease in cellular immune function. A previous study of academic-examination stress showed that, although a significant increase in EBV antibody titer occurred, indicating reactivation of EBV, no reactivation of CMV was observed [12] . However, Glaser et al. [13] showed increased titers of antibodies to herpesviruses in medical students during their final examinations. The increase in CMV antibody titer, as well as increased viral shedding, may indicate a greater degree of cellular immune suppression in astronauts than in the students.
Similar to our earlier findings [4] , large (i.e., up to 8-fold) increases in CMV antibody titer were observed after spaceflight. These findings suggest that replication of the virus occurred during spaceflight. Detection of CMV in the urine of subjects with serological reactivation supports this hypothesis, which is exemplified by astronauts 15 and 16, who exhibited significant postspaceflight increases in CMV antibody titer (figures 1B and 1C). None of the control subjects had a significant increase in CMV antibody titer. Moreover, astronauts 15 and 16, who had 4-fold increases in titer, were also CMV positive (urine) during spaceflight. Therefore, these 2 case reports underscore the importance of CMV reactivation during spaceflight. Although inflight blood samples were not available for measurement of stress hormones, increased levels of cortisol may have been partly responsible for increased CMV reactivation. Elevated plasma cortisol levels have been documented immediately after launch as well as throughout short-term spaceflights [1] , and increased glucocorticoids have been shown to enhance replication of CMV in human fibroblasts, epithelial cells, and macrophages [14] [15] [16] . Thus, stress responses associated with aspects of spaceflight (e.g., changes in gravitational forces) may have exacerbated CMV replication during spaceflight.
In agreement with findings in our previous study [4] , the levels of stress hormones at landing indicated an acute response upon returning to a 1-g environment. However, no differences in stress hormones were observed between the CMV-shedding astronauts and those not shedding virus. This is probably attributable to the general response to landing stresses, so that landing-day stress hormone values would not be expected to correlate well with latent CMV reactivation. Unavailability of stress hormone data at baseline precluded the direct correlation of cortisol levels and increased CMV shedding before spaceflight. Future studies will require additional in-flight samples, to determine the role of stress hormones in immune function and subsequent latent virus reactivation.
The ubiquitous nature of latent herpesviruses makes them ideal indicators for shedding of potentially infectious virus in saliva and urine during spaceflight. Moreover, the frequency and magnitude of latent herpesvirus reactivation may be a valuable tool for detecting asymptomatic changes in the immune system, allowing early intervention to prevent or limit clinical symptoms [3, 4] . Future studies on both shuttle and international space station crew members will include quantifying the viral (EBV and CMV) load in saliva, peripheral blood, and urine, in conjunction with measurements of stress and cellular immunity, to determine whether intervention is warranted.
